BONE RESORPTION MARKER BETA-CROSSLAPS FOR EARLY MONITORING OF OSTEOPOROSIS TREATMENT WITH DENOSUMAB
Antiresorptive long-term treatment for osteoporosis increases bone mineral density. Due to the long duration, poor compliance of patients to medication therapy is a big challenge. Bone mineral density measurements are recommended for the monitoring of treatment, but detectable changes may take up to...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Peytchinski Publishing,
2022-12-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Antiresorptive long-term treatment for osteoporosis increases bone mineral density. Due to the long duration, poor compliance of patients to medication therapy is a big challenge. Bone mineral density measurements are recommended for the monitoring of treatment, but detectable changes may take up to 2-3 years. Bone turnover markers can indicate changes in bone turnover rates earlier, and assessment their levels may be effective in enhancing compliance and clinical efficacy. Purpose: Our study aimed to assess whether the dynamics in serum levels of bone resorption marker beta-CrossLaps have a real practical benefit for early monitoring of postmenopausal osteoporosis treatment. Materials and methods: 21 Bulgarian women in menopause with newly diagnosed osteoporosis were studied. All participants hadn't been under treatment. Serum beta-CrossLaps levels were measured before and six months after subcutaneous administration of Denosumab - Injection 60 mg. Results: Serum concentrations before and six months after starting treatment were respectively 0.589 ± 0.266 ng/ml (0.06 - 1.2) and 0.166 ± 0.139 ng/ml (0.05 - 0.59). The beta-CrossLaps pre-treatment serum levels were within the reference range for the commercial kit used. After six months of treatment, there was a significant decrease in serum concentrations of about 72% from baseline. In our study, although pre-treatment levels were within the reference range, a significant decrease in concentrations was observed. Conclusions: The results show that the dynamics of beta-CrossLaps may be useful in the early monitoring of osteoporosis treatment. |
|---|---|
| Item Description: | 10.5272/jimab.2022284.4731 1312-773X |